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IntroductIon
Diffuse large B cell lymphoma (DLB CL) is one of the most 
frequent and aggressive B cell malignancies (Lenz and Staudt, 
2010). The activated B cell type of DLB CL (ABC-DLB CL) 
represents a particularly aggressive form, distinguished by 
constitutive activation of the canonical NF-κB transcription 
factor family and by poor patient survival and response to the 
standard treatment regimen of R-CHOP (Lenz and Staudt, 
2010). NF-κB transcription factors are normally activated by 
two key receptors for microbes on B cells, the B cell an-
tigen receptor (BCR) and the TLRs, and serve as essential 
inducers of normal B cell survival, growth, and differentiation 
(Thome, 2004; Gerondakis and Siebenlist, 2010; Hayden and 
Ghosh, 2012). Somatic mutations in CD79B and MYD88, 
affecting critical proteins for BCR and TLR signaling, re-
spectively, are recurrently found together in ABC-DLB CLs 
(Lenz et al., 2008; Davis et al., 2010; Ngo et al., 2011). It is not 
known if these mutations act cooperatively to dysregulate B 
cell survival, growth, or other functions or how cooperation 
and crosstalk might occur.
Missense mutations in MYD88 occur in 39% of cases 
of ABC-DLB CLs, with a single L265P amino acid substitu-
tion accounting for 75% of the mutations (Ngo et al., 2011). 
The same MYD88L265P mutation occurs in almost 100% of 
Waldenström macroglobulinemia (WM), 47% of IgM mono-
clonal gammopathy of undetermined significance, and 3–10% 
of chronic lymphocytic leukemia (Puente et al., 2011; Wang 
et al., 2011; Treon et al., 2012; Xu et al., 2013). MYD88 is 
an essential cytoplasmic adaptor protein, downstream from 
most TLRs and the IL-1/18 receptor, required to activate the 
IL-1 receptor–associated kinases (IRAKs) and NF-κB (Akira 
and Takeda, 2004). MYD88 has two distinct domains. A Toll/
IL-1R domain (TIR) promotes homotypic and heterotypic 
multimerization of MYD88 proteins upon recruitment to di-
merized TIR domains in the cytoplasmic tail of TLRs that 
have been engaged by their microbial ligands (Vyncke et 
al., 2016). A death domain forms a helical multimeric sig-
naling complex known as the Myddosome comprising six 
MYD88 molecules, four IRAK4 molecules, and four IRAK2 
molecules (Akira and Takeda, 2004; Lin et al., 2010). The 
MYD88L265P mutation in the TIR domain is predicted to 
cause allosteric changes in two binding surfaces and has been 
shown to promote multimerization with wild-type MYD88 
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and spontaneous formation of the MYD88-IRAK signaling 
complex, resulting in elevated NF-κB activity (Ngo et al., 
2011; Avbelj et al., 2014; Vyncke et al., 2016). When intro-
duced into mature mouse B cells by retroviral transduction, 
MYD88L265P is sufficient to initiate mitogen and T cell in-
dependent B cell proliferation that is terminated after sev-
eral cell divisions, in part by feedback inhibition of NF-κB 
(Wang et al., 2014). More recently, a mouse model bearing a 
conditional Myd88L252P allele has been described to develop 
lymphoproliferative disease with occasional transformation 
into clonal lymphomas (Knittel et al., 2016). Conversely, 
knockdown of MYD88 potently kills ABC-DLB CL cell 
lines, establishing that these tumors are addicted to MYD88 
activation for survival (Ngo et al., 2011).
Somatic mutations in CD79B occur in 21% of 
ABC-DLB CLs (Davis et al., 2010). CD79B and CD79A 
associate noncovalently with membrane immunoglobu-
lin, serving as the signal-transducing subunits of the BCR 
through an immunoreceptor tyrosine-based activation motif 
(ITAM) in the CD79B and CD79A cytoplasmic tails (Reth 
and Wienands, 1997). Upon antigen binding, the two tyro-
sines in each ITAM are phosphorylated by LYN and other 
SRC-family kinases, providing a docking site for the paired 
SH2 domains of SYK, activating SYK, and initiating the in-
tracellular signaling cascade (Cambier et al., 1994). 85% of 
CD79B mutations substitute the first ITAM tyrosine residue 
at position 196 (Y196) to another amino acid, most frequently 
histidine (Davis et al., 2010). Unlike MYD88 mutations, 
CD79B ITAM mutations do not spontaneously activate 
NF-κB in ABC-DLB CL cell lines (Lenz et al., 2008; Davis 
et al., 2010). Instead, CD79B ITAM mutations cause elevated 
surface BCR expression, possibly by inhibiting Lyn-mediated 
receptor internalization, resulting in higher surface BCR ex-
pression on ABC-DLB CLs but not in other tumors absent 
for CD79B mutations (Davis et al., 2010). In mice with a tar-
geted mutation substituting alanine in place of both tyrosine 
residues in the CD79B ITAM, the mature B cells displayed 
more BCRs on their surface, had delayed BCR internaliza-
tion after antigen binding, and had exaggerated BCR signal-
ing to calcium, extracellular signal-regulated kinase (ERK), 
and AKT but normal signaling to NF-κB (Gazumyan et 
al., 2006). Therefore, it is speculated that the likely role of 
CD79B mutation in the pathogenesis of ABC-DLB CL is by 
allowing B cells to respond inappropriately to BCR stimula-
tion by foreign or self-antigens (Rui et al., 2011). However 
this hypothesis remains to be tested experimentally.
One third of ABC-DLB CLs bearing the MYD88L265P 
mutation also have CD79B ITAM mutations (Ngo et al., 
2011). shRNA knockdown of CD79B and other components 
in BCR signaling in ABC-DLB CLs synergizes with shRNA 
against MYD88 in killing ABC-DLB CL cell lines in vitro, 
suggesting that BCR signaling through CD79B plays an im-
portant and nonredundant role in supplementing the growth 
and survival of MYD88L265P tumors (Ngo et al., 2011). In a 
phase 1/2 clinical trial of the Bruton tyrosine kinase (BTK) 
inhibitor ibrutinib, complete or partial responses occurred in 
four of five patients with ABC-DLB CL bearing both CD79B 
and MYD88L265P mutations, contrasting with zero of seven 
patients with MYD88L265P ABC-DLB CL without CD79B 
mutations (Wilson et al., 2015). However, it is not known 
if CD79B and MYD88 mutations cooperate to dysregulate 
normal B cell survival and growth or how such cooperation 
might impose dependency on BTK. Addressing this question 
may also illuminate fundamental mechanisms of synergistic 
and antagonistic crosstalk between antigen receptor and TLR 
signals in B cells (Rui et al., 2003, 2006).
B cells actively acquire tolerance to self-antigens 
through a series of bone marrow and peripheral lymphoid 
tissue checkpoints that inhibit B cell survival, growth, and 
plasma cell differentiation (Goodnow, 2007). B cells undergo 
multiple rounds of clonal proliferation upon binding to for-
eign antigen, but undergo anergy or apoptosis when their re-
ceptors are repeatedly engaged by self-antigens. Many human 
DLB CLs, and to a lesser extent follicular, marginal zone, and 
Burkitt’s lymphoma cells, express BCRs that are self-reactive 
because they use the VH4-34 element (Silberstein et al., 1991; 
Zhu et al., 1994; Hsu and Levy, 1995; Ottensmeier et al., 1998; 
Lossos et al., 2000; Young et al., 2015), which binds to human 
erythrocyte I-i polysaccharide antigen and human B lympho-
cyte CD45 O-linked polysaccharide antigen (Pascual et al., 
1991; Grillot-Courvalin et al., 1992). A recent study showed 
that self-antigen engagement of the BCR is required for the 
survival of some ABC-DLB CL cells, notably in a VH4-34+ 
lymphoma in which point mutations in the binding site 
that disrupt self I-i binding diminished the capacity of that 
BCR to support survival or growth of the lymphoma in tis-
sue culture (Young et al., 2015). In healthy people, VH4-34+ 
B cells with intact I-i binding sites are negatively selected 
against accumulating in the germinal center, memory B cell, 
or plasma cell repertoires (Pugh-Bernard et al., 2001; Reed et 
al., 2016). Therefore, a key question is whether CD79B muta-
tions disrupt normal peripheral B cell tolerance checkpoints 
and switch the B cell response to self-antigen from apoptosis 
into proliferation, as has been shown for CARD11 mutations 
(Jeelall et al., 2012).
Here, we analyze the consequences of CD79B mu-
tations in normal B cells and test if cooperation between 
MYD88 and CD79B somatic mutations disrupts periph-
eral self-tolerance checkpoints in B cells. We show that 
CD79B mutation on its own does not promote spontaneous 
growth or survival, nor does it block self-antigen–induced 
peripheral tolerance. However, extraordinary epistasis be-
tween CD79B and MYD88L265P occurs when coexpressed, 
blocking self-tolerance checkpoints and promoting sponta-
neous plasmablast differentiation. We show that MYD88L265P 
spontaneously triggers a block in intracellular processing 
and surface expression of BCRs similar to that observed 
in self-reactive B cells, and this block is relieved either by 
CD79B ITAM mutation or by increasing expression of 
wild-type CD79B. These findings reveal an unexpected, po-
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tent crosstalk and cooperation between mutations affecting 
the BCR and TLR signaling pathways and provide an ex-
planation for the frequent co-occurrence of MYD88 and 
CD79B mutations in ABC-DLB CLs.
resuLts
cd79B ItAM mutations do not drive B cell proliferation 
or nF-κB response genes
To model the acquisition by activated B cells of somatic 
mutations in MYD88 and CD79B, we transiently activated 
normal spleen B cells with a 6-h exposure to hen egg ly-
sozyme (HEL) antigen in vivo followed by 24-h culture 
with anti-CD40 antibody but no further exposure to BCR 
ligand. The activated B cells were then transduced with ret-
roviral vectors during a further 36-h culture with anti-CD40 
antibody but not BCR ligand, after which the cells were 
washed free of anti-CD40 and cultured in medium alone. 
When activated B cells are transduced with vectors encod-
ing MYD88L265P or CARD11L232LI and then placed back into 
culture with no mitogen, they are induced to divide repeat-
edly, in contrast to control cells transduced with empty vector 
or vectors encoding normal versions of these proteins, which 
do not divide but instead rapidly die (Jeelall et al., 2012; Wang 
et al., 2014). We therefore used the same assay to test if retro-
viral expression of CD79B bearing ITAM mutations found in 
lymphomas could also drive mitogen-independent cell prolif-
eration in otherwise normal B cells. We transduced activated 
mature B cells with bicistronic EGFP vectors encoding either 
wild-type CD79B or CD79B with missense mutations in the 
first ITAM tyrosine, corresponding to the recurring human 
Y196H or Y196F mutations (Davis et al., 2010), or a Y207F 
substitution in the second ITAM, or Y196F combined with 
Y207F (Fig. 1, A and B). After transduction, the cells were 
washed and placed back in culture for 3 d. In the absence of 
mitogen, the numbers of live EGFP+ B cells steadily declined 
at the same rate as empty vector transduced B cells that ex-
pressed only EGFP, and at the same rate as EGFP− cells in the 
same culture (Fig. 1 B). Thus, enforced expression of CD79B 
wild-type or mutants alone conferred no measurable survival 
advantage to primary B cells. Analysis of cell trace violet dilu-
tion also showed no induction of cell division (not depicted).
The cell surface proteins CD23 and CD25 are encoded 
by genes directly induced by NF-κB, and both are mark-
edly increased on primary B cells transduced with retroviral 
vectors encoding mutant alleles of CARD11 or IκB kinase 
β (IKK) found in human lymphomas (Wang et al., 2014). 
Using the same assay, expression of CD79B ITAM mutant 
proteins did not induce surface CD23 on EGFP+ cells relative 
to nontransduced EGFP− cells in the same culture, relative to 
EGFP+ cells expressing wild-type CD79B or empty vector 
(Fig.  1 C). Nor did the expression of CD79B ITAM mu-
tant proteins induce surface CD25 relative to EGFP+ cells 
expressing wild-type CD79B (Fig. 1 C).
Because Y196H is the most frequent CD79B mutation 
co-occurring with MYD88L265P (Davis et al., 2010), we next 
analyzed the consequences of CD79BY196H coexpressed with 
MYD88L265P. Coexpression of CD79BY196H and MYD88L265P 
failed to extend the transient phase of B cell proliferation 
induced by MYD88L265P alone in vitro (Fig. 1 D). The lack 
of any effect contrasts with the extended proliferation when 
MYD88L265P was combined with loss-of-function mutations 
in Tnfaip3 (A20) or Bcl2l11 (BIM) or gain-of-expression of 
Bcl2 (Wang et al., 2014). To assess whether CD79B mutation 
affected the negative feedback of NF-κB by MYD88L265P, we 
also measured NF-κB–inducible protein markers on doubly 
transduced B cells as previously described (Wang et al., 2014). 
As a positive control, we also transduced B cells with IKK 
bearing an activating mutation found in human lymphoma, 
which strongly induced CD23, CD25, and CD95 (Jeelall et 
al., 2012). In contrast, all markers were down-regulated relative 
to empty vector controls on B cells expressing MYD88L265P 
alone and were comparably down-regulated on B cells coex-
pressing CD79BY196H and MYD88L265P (Fig. 1 E). The lack of 
any measurable effect of CD79B in these assays contrasts with 
our previous findings, in which loss-of-function mutations in 
Tnfaip3 (A20) blocked MYD88L265P-induced down-regulation 
of CD23, CD25, CD86, and CD95 (Wang et al., 2014).
cd79B and MYd88 mutations have opposing and 
complementary effects on surface Bcr expression
Next we considered whether CD79B ITAM mutations af-
fected surface BCR expression on retrovirally transduced 
primary B cells, because lymphomas with CD79B mutations 
have elevated BCR expression (Davis et al., 2010). Activated 
mature B cells were transduced with retroviral vectors, cul-
tured in the absence of mitogen for 24 h, and analyzed by 
flow cytometry for surface CD79B and IgM. Compared with 
B cells transduced with empty vector, B cells expressing the 
wild-type CD79B retroviral vector had 150% increased sur-
face CD79B and surface IgM, while this was increased to 
200% of empty vector controls in cells expressing CD79BY196H 
(Fig.  2 A). In contrast, surface CD79B and IgM were dra-
matically decreased on EGFP+ cells expressing MYD88L265P 
alone, representing only 30% of the levels on empty vector 
EGFP+ cells (Fig. 2 B).
These convergent but opposing effects of mutant 
MYD88 and CD79B on BCR surface levels were then an-
alyzed in more detail. Surface IgM and CD79B were de-
creased by expression of the L265P mutant but not wild-type 
MYD88 (Fig.  2  C). A cell surface protein not part of the 
BCR complex, CD44, was unaffected. Dual expression of 
CD79BWT MYD88L265P or CD79BY196H MYD88L265P in 
B cells opposed the reduction of surface CD79B and IgM 
caused by MYD88L265P alone, resulting in receptor levels 
comparable to empty vector controls but lower than cells 
with the CD79B vectors but without MYD88L265P (Fig. 2 C).
These results revealed an unexpected inhibitory ef-
fect of MYD88L265P on surface IgM receptor levels. To test 
if this occurred at the level of gene transcription, we mea-
sured mRNAs encoding the four protein subunits required 
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Figure 1. cd79B ItAM mutations do not drive B cell proliferation or nF-κB activation. (A) Retroviral vector design for introducing wild-type/
mutant mouse Myd88 and/or Cd79b into activated B cells. (B) MD4 spleen B cells were activated in vivo by a single HEL injection 6 h before isolating spleen 
cells and washing and culturing them with anti-CD40 antibody but no BCR ligand for a total of 60 h, with retroviral spinoculation after the first 24 h. After 
activation and retroviral transduction, the cells were washed free of residual anti-CD40 and cultured in medium alone for the indicated times before flow 
cytometric analysis. The mean and standard deviation number of EGFP+ cells expressing empty vector, wild-type CD79B, or the indicated mutant CD79B 
are expressed relative to the number on day 0 of the culture. (C) Representative histograms (empty vector in gray, wild-type CD79B in blue) and mean 
fluorescence intensity (MFI) of cell surface CD23 or CD25 on EGFP+ cells on day 1 of culture without anti-CD40, relative to the MFI of nontransduced 
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for surface IgM display: Ighm encoding IgM μ-heavy chains, 
Igk encoding κ-light chains, Cd79a, and Cd79b. These were 
analyzed in microarray datasets of whole transcriptomes from 
EGFP+ B cells sorted from two independent cultures express-
ing empty vector, MYD88L265P, CARD11L232LI, or IKKK171E 
as previously described (Wang et al., 2014). As validation of 
the microarray data, Myd88 mRNA was increased 800% in 
samples of MYD88L265P transduced cells relative to all the 
other samples (Fig. 3 A). Consistent with the flow cytomet-
ric data in Fig. 1 E, the NF-κB target gene Fcer2a encoding 
CD23 was decreased in MYD88L265P-transduced cells rela-
tive to empty vector but increased in IKB KBK171E-transduced 
cells. In contrast, MYD88L265P did not decrease Ighm or Igk 
mRNA levels and only marginally decreased Cd79a and 
Cd79b (Fig. 3 A). To verify this result, EGFP+ cells expressing 
empty vector or MYD88L265P were sorted from three inde-
pendently transduced cultures of each, and cDNA was ana-
lyzed by quantitative PCR. This revealed increased Myd88 
mRNA in MYD88L265P-transduced cells but no significant 
difference in Ighm, Cd79a, or Cd79b mRNA (Fig. 3 B).
Because the decreased surface IgM could not be ex-
plained by changes at the mRNA level, we used Western 
blotting of sorted EGFP+ cell lysates to measure the relative 
amounts of CD79B and IgM proteins in the pre-Golgi or 
post-Golgi compartments. N-linked glycans on newly syn-
thesized (immature) CD79B and IgM μ-chains constitute 
high-mannose chains that can be cleaved by endoglycosidase 
H (Endo H), resulting in a shift to a lower molecular weight 
in SDS-PAGE. The N-linked carbohydrates are modified and 
become resistant to Endo H once the mature IgM-CD79A/B 
complex is assembled and transported through the trans-Golgi 
(Bell and Goodnow, 1994). Protein extracts from transduced 
and sorted EGFP+ B cells were treated with Endo H for 1 h at 
37°C or mock-treated, followed by separation on SDS-PAGE 
and Western blotting with antibodies against CD79B, μ-chain, 
and tubulin. In B cells expressing empty vector, most of the 
CD79B and IgM μ-chain was in the mature, slowly migrat-
ing, Endo H–resistant form (Fig. 3 C). In contrast, in B cells 
expressing MYD88L265P alone, IgM μ-chains were mostly im-
mature and Endo H–sensitive, and these accumulated mark-
edly (Fig. 3, C and D). In the same lysates, there was little 
change in the pool of immature CD79B, but there was a de-
crease in mature Endo H–resistant CD79B (Fig. 3, C and D). 
The pool of immature CD79B protein was increased in cells 
transduced with the CD79B vector, and coexpression of CD-
79BWT with MYD88L265P resulted in a higher proportion of 
μ-chains in the mature form and a decrease in the immature 
μ-chain pool (Fig. 3, C and D). Collectively, the mRNA and 
Western blotting analysis indicates that MYD88L265P triggers 
a post-translational block in IgM receptor trafficking to the 
trans-Golgi, resembling the trafficking block that explains 
low surface IgM in anergic self-reactive B cells (Bell and 
Goodnow, 1994). This IgM trafficking “checkpoint” could be 
relieved by increasing the pool of nascent CD79B protein, 
although future studies will need to determine how the in-
crease in CD79B reverses the effects of MYD88L265P.
effect of MYd88L265P on B cell transcriptome
The wider transcriptional effects of MYD88L265P were ex-
plored by analyzing the microarray datasets described above 
using the limma package (Ritchie et al., 2015), focusing on 
well-annotated genes with Entrez IDs. Using CAM ERA, a 
competitive test of enrichment suitable for small sample sizes 
and resistant to intergene correlation (Wu and Smyth, 2012), we 
first queried for enrichment of differentially expressed genes 
against predefined sets of hallmark, curated, and immunological 
signature gene sets defined in MSigDB (Table S1; Subramanian 
et al., 2005). We focused on evidence for differential expres-
sion between MYD88L265P- and CARD11L232LI-transduced 
B cells because both cell populations were actively prolifer-
ating at the time of RNA isolation, unlike empty vector–
transduced cells, and because CD79B mutations appear to be 
coselected with MYD88L265P in human lymphomas but not 
obviously with CARD11 mutations.
Hallmark gene set M5890, comprising 207 genes reg-
ulated by NF-κB in response to TNF, was one of three hall-
mark gene sets most significantly enriched for differentially 
expressed genes between MYD88L265P- and CARD11L232LI- 
expressing B cells (false discovery rate [FDR] = 7.78 × 10−6; 
Table S2). The majority of NF-κB–induced mRNAs in this set 
were decreased in MYD88L265P-expressing B cells (Fig. 4 A), 
consistent with our previous evidence that MYD88L265P in 
transduced B cells induces negative feedback inhibition of 
NF-κB through TNF AIP3 (Wang et al., 2014).
Gene set M1487, comprising 55 genes that are 
up-regulated in plasma cells relative to other B cell develop-
mental stages (Mori et al., 2008), was one of two curated gene 
sets most significantly enriched for differentially expressed 
genes between MYD88L265P- and CARD11L232LI-expressing 
B cells (FDR = 1.68 × 10−12; Table S3). The majority of 
the plasma cell up-regulated gene set was increased in 
MYD88L265P-expressing cells (Fig. 4 B). This set was one of 
the four most significantly enriched gene sets of all queried 
sets in MSigDB (Table S1). The three other gene sets with 
EGFP− control cells in the same culture, measured in independent triplicate cultures. Cells were transduced with vectors encoding no CD79B (-) or CD79B 
with the indicated substitutions at Tyr 196 or Tyr207. Statistical analysis by ANO VA. (D) Mean and SD number of EGFP− or EGFP+ cells transduced with the 
indicated vectors and cultured without anti-CD40 relative to the number on day 0 of the same culture. (E) CD23, CD25, CD86, and CD95 MFI on EGFP+ 
cells expressing the indicated vectors in independent triplicate cohorts of cells relative to MFI of nontransduced EGFP− cells after 1 d of culture without 
anti-CD40. Statistical analysis by ANO VA with Tukey’s positive test comparing the indicated groups: *, P < 0.05; **, P < 0.01; ***, P < 0.001. Data are repre-
sentative of at least three independent experiments.
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comparably small FDR values all constitute genes increased 
in myeloid cell differentiation, which were decreased in 
MYD88L265P-expressing cells.
When the transcriptome of MYD88L265P-expressing 
B cells was compared with empty vector–expressing B cells 
using limma, 111 genes had strong evidence for differential 
expression with 88 increased in MYD88L265P cells (Fig. 4 C 
and Table S4). Compared with CARD11L232LI-expressing B 
cells, 84 genes had strong evidence for differential expression 
in MYD88L265P B cells, with 30 increased, including the plasma 
cell–induced genes Prdm1 and Igj (J-chain; Fig. 4 D). Com-
paring MYD88L265P B cells with all the other groups yielded 
22 probe sets with strong evidence of differential expression 
in MYD88L265P-transduced cells relative to all the other cell 
types examined, and all were increased in MYD88L265P cells. 
Ranked by fold change relative to CARD11L232LI-expressing 
cells, they were Hnf1b, Tmed6, Myd88, Mybl1, Pcbd1, Map2, 
Nqo1, Gm10558, Prdm1, Chac2, Rnd3, Ccl3, Tnip3, Fam46c, 
Ccr9, Ehf, Cdc14b, Slco4c1, Depdc7, Sfmbt2, Fam81a, and 
Fam135a. Myd88 was expected on the basis of the analysis 
Figure 2. cd79B and MYd88 mutations have opposing effects on surface Bcr expression. Spleen cells from C57BL/6 mice were cultured for 24 h 
with anti-IgM and anti-CD40 to activate B cells. Activated B cells were then washed, spinoculated with retroviral supernatants, and cultured for a further 
36 h with anti-IgM and anti-CD40. The transduced cells were then washed free of residual anti-IgM and anti-CD40 and placed into fresh triplicate cultures 
without any mitogen for 24 h before staining with antibodies to cell surface CD79B and IgM and flow cytometry. (A) Representative histograms and graphs 
displaying mean fluorescence intensity (MFI) of surface CD79B or IgM on EGFP+ cells in independent cultures of cells transduced with EGFP only empty 
vector (gray) or vectors encoding wild-type or indicated mutant CD79B (blue). In the graphs, the MFI for each cohort of EGFP+ cells is expressed relative 
to the MFI of nontransduced EGFP− control cells in the same culture. (B and C) Representative histograms (red, MYD88; blue, CD79B; purple, dual CD79B 
and MYD88) and MFI of EGFP+ B cells transduced with the indicated vectors and staining for cell surface CD44 as a control protein not part of the BCR 
complex. EV, empty vector. Graphs in C show means and SDs of EGFP+ cells in independent triplicate cultures. Data are representative of two independent 
experiments. Statistical analysis by ANO VA with Tukey’s positive test comparing the indicated groups: *, P < 0.05; **, P < 0.01.
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Figure 3. MYd88L265P mutation down-regulates surface IgM by inhibiting intracellular Bcr maturation. (A) After activation, transduction, washing 
free of anti-CD40, and 24-h culture without mitogen, EGFP+ B cells expressing empty vector (EV), MYD88L265P, CARD11L232LI, or IKKK171E were sorted from 
n = 2 independent cultures for B cells expressing each vector type. RNA was isolated and analyzed on Affymetrix microarrays. Shown is normalized signal 
in arbitrary units for Myd88, Ighm, Igk, Fcer2a (CD23), Cd79a, and Cd79b. Statistical analysis by one-way ANO VA with Tukey’s positive test comparing the 
indicated groups with EV cells: *, P < 0.05; ***, P < 0.001. (B) Quantitative PCR quantitation of Myd88, Ighm, Cd79a, and Cd79b mRNA in EGFP+ cells express-
ing EV or MYD88L265P sorted from an independent set of triplicate cultures (denoted by different colors) and measured in triplicate. Statistical analysis by 
Student’s t test: **, P < 0.01. (C) EGFP+ B cells expressing the indicated vectors were sorted after 1-d culture without anti-CD40 (2.5 d since last exposure to 
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above (Fig. 3), validating the limma analysis. Tnip3 encodes 
a negative regulator of NF-κB that interacts with TNF AIP3 
(Verstrepen et al., 2014). Fam46c is a member of the curated 
plasma cell up-regulated gene set M1487 (Mori et al., 2008) 
and is frequently deleted or mutated in human multiple my-
eloma (Lohr et al., 2014).
MYd88L265P and cd79B mutations cooperatively drive 
plasmablast differentiation
Because B cell receptor signaling is critical for B cell sur-
vival and differentiation in vivo, we next asked if the 
CD79BY196H mutations would allow differentiation of 
MYD88L265P-expressing B cells into plasmablasts when 
transplanted into Rag1-deficient mice, as observed for 
cells expressing single gain-of-function CARD11 muta-
tions (Jeelall et al., 2012). Plasmablast differentiation from 
polyclonal C57BL/6 B cells could theoretically have been 
driven by BCRs that bound to self- or microbe antigens; 
therefore for these experiments we used HEL-specific B 
cells from MD4 transgenic mice that received no BCR 
stimulation after retroviral transduction and transplanta-
tion in vivo. HEL and anti-CD40 activated B cells were 
transduced with CD79B and/or MYD88 vectors, washed, 
and transplanted into Rag1−/− recipient mice and analyzed 
in the spleen after 11 d.
Gating on the EGFP+ subset of transferred B cells re-
vealed that those expressing CD79BWT MYD88L265P or 
CD79BY196H MYD88L265P vectors accumulated in greater 
numbers and had lower CD19 and B220 expression com-
pared with B cells expressing MYD88L265P alone (Fig.  5, 
B–E). CD19 and B220 are two B cell lineage markers that 
are repressed upon differentiation into plasma cells (Nutt et 
al., 1998). CD19 and B220 down-regulation on CD79BY196H 
MYD88L265P B cells paralleled the phenotype of Tlr9−/− 
MYD88L265P B cells that undergo plasmablast differentiation 
after transplantation to Rag1−/− recipients (Wang et al., 2016) 
and B cells transduced with gain-of-function CARD11 mu-
tation (Jeelall et al., 2012). After correcting for the number of 
EGFP+ cells transplanted on day 0 (Fig. 5 A), MYD88L265P 
B cells were present in 5-fold higher number than empty 
vector B cells on day 11, and CD79BWT MYD88L265P or CD-
79BY196H MYD88L265P B cells accumulated to 8- and 15-fold 
higher numbers, respectively (Fig. 5 C).
Plasma cell differentiation was further analyzed by 
transducing polyclonal C57BL/6 B cells, transplanting them 
into Rag1−/− recipients, and analyzing the recipients 11 d 
later (Fig. 5, F–I). CD19 was significantly decreased on IgM+ 
EGFP+ cells coexpressing MYD88L265P with CD79B or CD-
79BY196H compared with control cells expressing only one 
or other protein (Fig. 5 F). In contrast, surface IgM was in-
creased on the cells coexpressing MYD88L265P with CD79B 
or CD79BY196H compared with cells expressing MYD88L265P 
alone, the latter having lower surface IgM than empty vec-
tor–expressing B cells (Fig. 5 G). Down-regulation of CD19 
was accompanied by induction of CD138 and by secre-
tion of large amounts of serum IgM in recipients of cells 
coexpressing MYD88L265P with CD79B or CD79BY196H 
(Fig. 5, H and I; and Fig. S2). Interestingly, there was no de-
tectable secretion of IgG, indicating that the cooperation 
between MYD88L265P and CD79B drives plasma cell dif-
ferentiation but not isotype switching to IgG. These results 
are similar to the down-regulation of CD19 and B220, in-
duction of CD138, and secretion of IgM but not IgG by 
C57BL/6 B cells expressing MYD88L265P combined with 
TLR9-deficiency (Wang et al., 2016).
Abnormal cd79B and MYd88L265P cooperatively 
break tolerance checkpoints
Gain-of-function CARD11 mutations derived from human 
lymphomas disrupt several B cell tolerance checkpoints when 
introduced into activated mouse B cells, switching the ef-
fect of self-antigen from inducing apoptosis into induction of 
proliferation and plasmablast differentiation and autoantibody 
secretion (Jeelall et al., 2012). Using the same experimental 
system, MYD88L265P did not protect B cells from self-antigen–
induced deletion unless combined with enforced BCL2 ex-
pression, and the MYD88L265P BCL2 combination remained 
insufficient to break tolerance checkpoints that oppose 
plasmablast differentiation and autoantibody secretion (Wang 
et al., 2014). Hence we used the identical experimental model 
to test if cooperation between CD79B and MYD88 muta-
tions would override peripheral tolerance checkpoints in 
self-antigen–binding B cells transferred to antigen-expressing 
recipient mice. Mature MD4 IgHEL-transgenic B cells bear-
ing HEL-specific BCRs were activated, transduced with the 
CD79B and MYD88 single or combined retroviral vectors, 
and transplanted into ML5-transgenic Rag1−/− recipient mice 
that expressed HEL protein in their circulation as self-antigen 
(Goodnow et al., 1988).
The number of surface HEL-binding IgMa+EGFP+ 
B cells was measured at the time of transplantation (input) 
and in the spleen of the recipients 11 d after transplanta-
tion (Fig.  6, A and C). Retrovirally transduced EGFP+ B 
cells expressing no additional protein or only MYD88L265P 
were eliminated by self-tolerance, as were EGFP+ B cells 
expressing only CD79BWT or CD79BY196H (Fig.  6, B and 
anti-CD40 or anti-IgM). Cell lysates were treated with Endo H or buffer only before SDS-PAGE and Western blotting with antibodies against mouse CD79B, 
IgM μ-chain, and tubulin as a loading control. Arrows indicate position of immature CD79B or μ-chain after Endo H cleavage of high-mannose N-glycans 
and slower migrating mature proteins with complex N-glycans resistant to Endo H. (D) Densitometry analysis of the Western blot in C, showing the relative 
abundance of mature Endo H–resistant and immature Endo H–sensitive CD79B and μ-chains compared with tubulin loading control in each sample. Data 
are representative of three independent experiments.
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C), indicating that the CD79B ITAM mutation on its own 
did not disrupt this tolerance checkpoint. In contrast, B cells 
coexpressing CD79BWT or CD79BY196H with MYD88L265P 
were protected from self-antigen-induced deletion (Fig.  6, 
B and C). On average, 10 to 30 times more EGFP+ cells 
accumulated when the transplanted B cells were CD79BWT 
MYD88L265P or CD79BY196H MYD88L265P, respectively, 
compared with recipient mice that received B cells express-
ing only one or other mutant protein (Fig. 6 C). Inhibiting 
the peripheral deletion checkpoint therefore required co-
Figure 4. effect of MYd88L265P on global rnA expression in B cells. Global analysis using limma of the RNA Affymetrix microarray dataset in Fig. 3 A, 
from two independent cultures of EGFP+ cells expressing empty vector, MYD88L265P, CARD11L232LI, or IKKK171E. (A and B) CAM ERA, a competitive test of enrich-
ment suitable for small sample sizes and resistant to intergene correlation, was implemented in the limma package to test the entire dataset for enrichment 
of hallmark, curated, and immunological signatures gene set defined in MSigDB. Shown are (A) the third most significantly enriched hallmark gene set and 
(B) the second most significantly enriched curated gene set. A complete list of enriched gene sets is provided in Table S1. (C and D) The limma package was 
used to compare normalized RNA signals in MYD88L265P-expressing cells with (C) empty vector–expressing cells or (D) CARD11L232LI-expressing cells. The 
y-axis shows the mean expression signature for each probe set across all eight samples; the x-axis shows the mean and 95% confidence interval for the 
fold change in expression of each probe set in MYD88L265P cells compared with (C) empty vector cells and (D) CARD11L232LI cells. Probe sets are color-coded 
by strength of evidence for differential expression, and those with highest fold change are marked with corresponding gene symbol.
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operation between dysregulated CD79B and MYD88L265P. 
Moreover, self-reactive B cells coexpressing CD79BWT 
MYD88L265P or CD79BY196H MYD88L265P differentiated into 
CD19low plasmablasts (Fig. 6 B). Analysis of the serum from 
the recipients by ELI SA showed secreted anti-HEL autoanti-
bodies only in recipients of B cells with dysregulated CD79B 
and mutant MYD88 (Fig. 6 D), indicating that cooperation 
between the mutations caused a potent disruption to B cell 
tolerance checkpoints.
Break of B cell tolerance by combining cd79B and MYd88 
mutations correlates with surface Bcr levels
Transcription of CD79BWT from the retroviral promoter 
increased CD79B and IgM on the surface of transduced 
B cells to a similar amount compared with the CD79B 
ITAM mutation (Fig. 2, A and B) and increased the pool of 
pre-Golgi Endo H–sensitive CD79B (Fig. 3 C). We there-
fore sought to diminish translation of the retroviral CD79B 
transcript with the aim of distinguishing the effect of 
Figure 5. MYd88L265P  and cd79B muta-
tions cooperate to promote plasmablast 
differentiation. (A–E) MD4 transgenic B 
cells were transduced with empty vector or 
vectors expressing MYD88L265P alone (LP) or 
combined with wild-type CD79B (WT) or CD-
79BY196H (YH). (A) Number of live EGFP+ B cells, 
each cell likely to represent an independent 
transduction event, transplanted into each 
Rag1−/− recipient mouse. (B) Flow cytometric 
analysis of the spleen of recipient mice 11 d 
after transplantation, showing concatenated 
data from three to five recipients per treat-
ment. Top row: mean percentage of IgM+ 
HEL-binding donor-derived B cells among live 
leukocytes; bottom row: mean percentage of 
EGFP+ cells among IgM+ HEL-binding cells and 
CD19 expression on these cells. (C) Number of 
live EGFP+ B cells in the spleen of individual re-
cipients 11 d after transplantation. Bars denote 
arithmetic means. (D and E) Mean fluorescence 
intensity (MFI) of CD19 and B220 measured on 
IgM+ HEL-binding EGFP+ B cells. Data are rep-
resentative of three independent experiments. 
(F–I) C57BL/6 B cells were transduced with 
the indicated vectors and transplanted into 
Rag1−/− mice. Eleven days later, IgM+ EGFP+ 
cells were analyzed in the spleen, measuring 
MFI of (F) CD19 and (G) MFI of cell surface IgM 
in individual recipients. Data are representative 
of two independent experiments. (H) At the 
same time, serum IgM (circle) and IgG (square) 
were measured in individual recipients. (I) The 
percentage of IgM+ EGFP+ cells expressing 
CD138 was measured in a separate experiment 
(Fig. S2). Statistical analysis by ANO VA with 
Tukey’s positive test comparing the indicated 
groups with empty vector and MYD88L265P cells 
(**, P < 0.01; ***, P < 0.001) or comparing with 
EV only, #, not statistically significant.
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CD79BY196H from that of CD79BWT. CD79B translation 
was diminished by introducing one of six different up-
stream open reading frames into the 5′ untranslated region 
(5′ UTR) of the CD79B coding sequence (Fig. S1; Calvo 
et al., 2009). When cell surface CD79B was measured on 
the transduced B cells with the same level of EGFP ex-
pression, the 5′ UTR variants decreased the CD79B mean 
fluorescence intensity compared with B cells expressing 
the CD79BWT with the typical Kozak sequence (Fig. 7 A). 
Two 5′ UTR sequences were also tested for their effects on 
surface IgM expression. Whereas surface IgM and CD79B 
were twice as high on EGFP+ cells expressing CD79BWT 
cDNA compared with cells expressing the control EGFP 
vector alone, both were decreased to levels comparable with 
the control cells when the CD79BWT cDNA carried the 
UTR4 insertion and were increased by only 35% when the 
UTR6 insertion was present (Fig. 7 B).
To test the effects of these translationally dampened 
CD79B vectors on peripheral B cell tolerance check-
points, we transduced HEL-specific B cells with the 
CD79BWT MYD88L265P or CD79BY196H MYD88L265P vec-
tors preceded by UTR4 or UTR6 and transplanted the B 
cells into HEL-transgenic mice as before (Fig.  7  C). After 
5 d, HEL-specific EGFP+ B cells expressing empty vector, 
MYD88L265P alone, CD79BWT alone, or CD79BY196H alone 
did not persist in the recipient mice expressing HEL anti-
gen, but B cells expressing the CD79BWT MYD88L265P or 
CD79BY196H MYD88L265P vectors resisted deletion to varying 
extents (Fig. 7 D). On average, twice the number of EGFP+ 
B cells persisted when they expressed the higher expression 
UTR6 vector compared with the UTR4 vector (Fig. 7 D). 
Furthermore, B cells expressing the UTR6 CD79BY196H 
MYD88L265P vector preferentially accumulated on average to 
twice the number of B cells expressing UTR6 CD79BWT 
Figure 6. combined MYd88L265P and 
cd79B mutations break B cell tolerance to 
self-antigen in vivo. (A) Number of live EGFP+ 
MD4 IgHEL-transgenic B cells transduced with 
EGFP vectors encoding the indicated addi-
tional proteins (-, no CD79B or MYD88 protein; 
WT, wild-type protein; LP, L265P; YH, Y196H) 
transplanted into each ML5 HEL-transgenic 
Rag1−/− recipient mouse in two independent 
experiments. (B) Flow cytometric analysis of 
the spleen of recipient mice 11 d after trans-
plantation, showing concatenated data from 
three recipients per treatment. Top: percent-
age of IgMa+ HEL-binding donor-derived B 
cells among live splenic leukocytes; bottom: 
mean percentage EGFP+ cells among IgMa+ 
HEL-binding donor B cells and CD19 expres-
sion on these cells. (C) Number of live EGFP+ 
IgMa+ HEL-binding B cells in the spleen of each 
recipient mouse. Data are pooled from two 
independent experiments, each with n = 3 or 
4 per group. Bar denotes arithmetic mean. (D) 
HEL-binding IgM antibody in serum of individ-
ual recipients, measured by ELI SA. O.D., optical 
density. Statistical analysis by ANO VA with 
Tukey’s positive test comparing the indicated 
groups with empty vector (EV) and MYD88L265P 
cells: **, P < 0.01; ***, P < 0.001.
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Figure 7. checkpoint inhibition by cd79B and MYd88 mutations correlates with amount of surface Bcr expressed. (A) MD4 HEL-specific B cells 
were activated and transduced with bicistronic EGFP retroviral vectors encoding no additional protein (-), Cd79bWT with normal 5′ UTR, Cd79bY196H (YH), 
or Cd79bWT with one of six different open reading frame insertions in the Cd79b 5′ UTR (5′ UTR1–6; Fig. S1). After washing, n = 5 independent cultures of 
cells transduced with each vector were established without antigen or CD40 stimulation and analyzed 24 h later by flow cytometry for cell surface CD79B 
mean fluorescence intensity (MFI) gated on cells expressing equivalent level of EGFP. Bars denote arithmetic means. Statistical analysis by one-way ANO VA 
with Tukey’s positive test comparing the indicated groups. (B) Independent experiment as in (A), analyzed for cell surface CD79B and IgM. (C–E) HEL-specific 
B cells were transduced with vectors encoding Myd88L265P, Cd79bWT, Cd79bY196H, without or with the 5′ UTR 4 or 6 insertions. The cells were transplanted 
to HEL-transgenic Rag1−/− recipients. (C) Number of EGFP+ B cells transplanted into each recipient mouse; n = 2 independent experiments. (D) Number of 
EGFP+ B cells in the spleen of each recipient 5 d after transplantation. Data are pooled from two independent experiments, each with n = 3–5 recipients per 
group. Bars are arithmetic means. Statistical analysis by ANO VA with Tukey’s positive test comparing the indicated groups with empty vector and MYD88L265P 
cells: *, P < 0.05. (E) Number of EGFP+ B cells in each recipient plotted against the mean fluorescence intensity of CD79B and IgM on the EGFP+ cells in the 
same mouse at the time of enumeration. Symbols as in D. Statistical analysis by linear regression. Data are representative of two independent experiments.
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MYD88L265P (Fig. 7 D). Although the number of self-reactive 
EGFP+ B cells resisting deletion was variable, it was strongly 
correlated with their surface CD79B and IgM expression 
in the recipient mice (Fig. 7 E), indicating that escape from 
self-tolerance by MYD88L265P B cells required increased BCR 
expression through cooperation with alterations in CD79B.
dIscussIon
CD79B and MYD88 mutations frequently occur together 
in mature B cell malignancies. Here we reveal that they co-
operate synergistically to induce B cell differentiation into 
plasmablasts and break self-tolerance checkpoints in B cells 
within peripheral lymphoid tissue. What might be the basis 
for the striking cooperation between CD79B and MYD88 
mutations in our experiments?
Several lines of evidence here support a conclusion that 
surface BCR density is governed by CD79B and represents a 
critical, rate-limiting factor for B cells expressing MYD88L265P. 
First, CD79B appears to be the rate-limiting component for 
surface BCR expression in normal B cells, because retrovi-
rally increasing the expression of CD79B increased the mean 
surface IgM to 150% of controls, and this could be further 
increased if the retrovirally expressed CD79B carried tyro-
sine substitutions in the membrane proximal ITAM found 
recurrently in human lymphomas (Davis et al., 2010). Second, 
B cells expressing MYD88L265P down-regulate their surface 
CD79B and IgM despite having no decrease in mRNA for all 
four essential components of surface IgM BCRs. Low surface 
IgM expression in MYD88L265P B cells is instead explained 
by accumulation of immature, pre-Golgi, Endo H–sensitive 
IgM, representing a “checkpoint” remarkably similar to the 
posttranslational block to surface IgM expression induced 
by chronic binding to self-HEL antigen (Bell and Good-
now, 1994). Hence it is conceivable that the expression of 
MYD88L265P and chronic exposure to self-antigen act addi-
tively or cooperatively to block surface BCR trafficking and 
accumulation on the cell surface, which may deprive the cells 
of tonic BCR survival signals to counter B cell apoptosis in 
vivo. The third line of evidence that CD79B represents a crit-
ical limiting factor in B cells expressing MYD88L265P comes 
from the experiment introducing 5′ UTR open reading 
frames that compete with the normal translation initiation of 
retrovirally encoded CD79B protein. The decrease in CD79B 
and IgM surface display was correlated with a decrease in 
the capacity of CD79B to block deletion of HEL-specific 
B cells when combined with MYD88L265P. In this case, the 
rescue of mature B cells from self-antigen induced deletion 
was enhanced by Y196H mutation and correlated with in-
creased surface CD79B and IgM.
Previous studies have shown that the deletion of 
HEL-specific B cells in HEL-transgenic mice is preceded by 
down-regulation of surface IgM and is mediated by apoptosis 
that is inhibited by Bcl2 overexpression (Cyster et al., 1994) 
and requires the BCL2 antagonist BIM (Enders et al., 2003). 
When the capacity to synthesize surface IgM is experimen-
tally ablated by conditional gene deletion, mature B cells un-
dergo apoptosis in FOXO1-dependent and BIM-dependent 
manner that is also inhibited by enforced expression of BCL2 
(Lam et al., 1997; Srinivasan et al., 2009). B cells that lose 
surface IgM have decreased phosphorylation of AKT, an in-
termediate in phosphoinositide 3-kinase (PI3K) inhibition of 
FOXO1, and can be protected against apoptosis by mutations 
that constitutively activate PI3K (Srinivasan et al., 2009). Con-
versely, exaggerated surface IgM accumulation and increased 
AKT activation occurs in B cells with substitutions in both 
ITAM tyrosines in CD79B (Gazumyan et al., 2006). These 
results are consistent with the view that surface IgM paired 
with CD79A and CD79B, in the absence of antigen, continu-
ously signals through the ITAMs in CD79A to activate PI3K 
at a tonic level and thereby activate AKT, inhibit FOXO1 
accumulation, and repress BIM formation in B cells to pro-
mote their survival. Thus, the BIM-dependent deletion of 
HEL-specific B cells that follows self-antigen-induced BCR 
down-regulation may therefore result, at least in part, from the 
loss of surface BCR CD79A tonic signaling to PI3K. Because 
MYD88L265P decreases surface BCR even in the absence of 
self-antigen, any prosurvival signal induced by MYD88L265P, 
for example through the activation of NF-κB, may be over-
whelmed by the loss of surface BCR and its PI3K survival 
signal. Our previous work showing the striking cooperation 
between Bcl2 overexpression and MYD88L265P for enhancing 
B cell survival both in the absence or presence of self-antigen 
supports the idea that the capacity of MYD88L265P to promote 
B cell survival and proliferation is normally overwhelmed by 
BIM-mediated apoptosis (Wang et al., 2014).
Notably, overexpression of neither CD79BWT nor 
CD79BY196H alone was sufficient to block self-antigen-induced 
deletion. One explanation is that preserving tonic BCR sig-
naling to PI3K alone is insufficient to counter other induc-
ers of apoptosis, including the elevation of BIM and Nur77 
(Healy et al., 1997; Glynne et al., 2000; Zikherman et al., 
2012). When MYD88L265P is then coexpressed with CD79B 
vectors in self-reactive B cells, MYD88L265P-IRAK signaling 
to activate NF-κB may counter additional proapoptotic me-
diators by inducing prosurvival proteins such as BCL-XL and 
A1, which are not normally induced by self-antigen activa-
tion of the BCR (Glynne et al., 2000).
In addition to cooperating to block self-antigen– 
induced B cell deletion, the combination between CD79B 
and MYD88 mutations also overrides the B cell tolerance 
checkpoint that normally inhibits TLR9- or TLR4-driven 
self-reactive B cell differentiation into CD19low plasmab-
lasts (Rui et al., 2003, 2006). This checkpoint is induced by 
chronic self-antigen engagement and BCR signaling to ERK 
(Rui et al., 2003, 2006). ERK phosphorylates and promotes 
the activity of an essential inhibitor of plasmablast differentia-
tion, ETS1 (Bories et al., 1995; Hollenhorst et al., 2011). The 
promotion of plasmablast differentiation by CD79B was not 
simply a result of enhanced survival of self-reactive B cells, 
because overexpressing BCL2 enhances the accumulation of 
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MYD88L265P-expressing B cells but not their differentiation 
into CD19low plasmablasts (Wang et al., 2014).
The microarray data identified increased expression of 
plasma cell up-regulated genes in MYD88L265P-expressing 
B cells compared with CARD11L232LI-expressing B cells, 
raising the possibility that MYD88L265P alone initiates an 
abortive plasma cell differentiation program that requires an 
additional signal from the BCR to be completed. Weaker 
gain-of-function alleles of CARD11 do not spontaneously 
drive B cell differentiation into plasmablasts unless the cells 
receive an additional BCR stimulus by binding self-antigen 
(Jeelall et al., 2012). Elevated surface BCR caused by CD79B 
mutations or overexpression could provide an additional signal 
through PI3K activation to drive plasmablast differentiation 
by down-regulating ETS1. Several independent observations 
support this hypothesis: (1) the activation of PI3K p100 delta 
subunit regulates autoantibody formation by marginal zone 
and B1 B cells (Durand et al., 2009), (2) constitutively active 
PI3K ensures mature B cell survival even in the absence of 
IgM (Srinivasan et al., 2009), and (3) PI3K activation is in-
volved in reducing Ets1 levels during plasma cell differentia-
tion (Luo et al., 2014). Similar to enhanced BCR signaling by 
CD79B mutations, B cell differentiation into plasmablasts in 
mice is exaggerated by other mutations that dysregulate BCR 
signaling, including loss-of-function mutations in Lyn, Ptpn6 
(SHP1), and Cd22, resulting in lupus-like symptoms such 
as pathogenic autoantibody production (Chan et al., 1997; 
Gross et al., 2009; Luo et al., 2014). These observations are 
likely due to the loss of Ets1 expression, because Ets1 is con-
trolled by BCR-mediated signals through PI3K, BTK, IKK, 
and JNK (Luo et al., 2014). Additionally, Ets1 deficiency also 
leads to B cell hyper-responsiveness to TLR9 stimulation and 
TLR9-dependent autoimmunity in mice (Wang et al., 2005). 
Therefore, in future studies, it will be interesting to test if the 
observed phenotype in CD79B and MYD88 double-mutant 
B cells results from PI3K activation to down-regulate ETS1.
CD79B mutations are seen in only 30% of MYD88L265P 
ABC-DLB CL and 15% of WM (Ngo et al., 2011; Poulain et 
al., 2013), suggesting that other mechanisms may exist to an-
tagonize the MYD88L265P effect on CD79B and IgM traffick-
ing through the Golgi to the cell surface. Indeed, Lyn copy 
number loss is found in 60% of patients with WM (Hunter 
et al., 2014). Lymphoma B cells with the CD79B ITAM mu-
tation show reduced Lyn activity, suggesting that the effect 
of CD79B ITAM mutation could also be achieved by Lyn 
deficiency (Davis et al., 2010). In mice, Lyn deficiency results 
in exaggerated B lymphoblast expansion, autoantibody pro-
duction, and elevated sensitivity to BCR stimulation (Chan 
et al., 1997; Cornall et al., 1998). Additionally, Lyn deficiency 
in mice causes hypersensitivity to MYD88 signaling, and this 
MYD88-dependent signaling is crucial for autoimmunity 
(Lamagna et al., 2013, 2014). However, one might question 
why ABC-DLB CLs with CD79B and MYD88 mutations re-
sist differentiation and cell cycle arrest. One clue comes from 
clinical observations that 23% of human DLB CL cases have 
chromosome 11q24.3 gain to elevate Ets1 and Fli1 expres-
sion to antagonize B cell differentiation (Bonetti et al., 2013). 
Additional mechanisms of differentiation block in DLB CL 
come from the frequent inactivation of PRDM1 in up to 
24% of ABC-DLB CLs by chromosome 6q21-q22.1 deletion 
(Pasqualucci et al., 2006). Furthermore, 77% of these tumors 
lack the BLI MP1 protein despite the presence of PRDM1 
mRNA (Pasqualucci et al., 2006). Therefore, different disease 
outcomes could result from additional mutations among the 
average 20 or more protein-altering mutations B cells acquire, 
which includes CD79B and MYD88 mutations.
MAterIALs And MetHods
Mice
Splenic B cells were collected from C57BL6 mice or MD4 
mice bearing rearranged transgenic immunoglobulin gene 
encoding for HEL-specific antibodies (IgHEL transgenic; 
Goodnow et al., 1988). All mice were generated on a C57BL6 
background or backcrossed to that background for greater 
than 10 generations and were housed in specific pathogen–
free environment at the Australian Phenomics Facility, Aus-
tralian National University. Donor mice were aged 8–16 wk 
at the time of the experiments. Rag1−/− and Rag1−/− ML5 
transgenic mice that express soluble HEL (Goodnow et al., 
1988) were used as recipients at ages 8–14 wk. All animals 
used in this study were cared for and used in accordance with 
protocols approved by the Australian National University 
Animal Experimentation Ethics Committee and the current 
guidelines from the Australian Code of Practice for the Care 
and Use of Animals for Scientific Purposes.
retroviral vectors and packaging
Mouse Cd79b was amplified by Platinum Pfx DNA poly-
merase (Invitrogen) from mouse splenic cDNA and sub-
cloned into pcDNA3.1(+) vector. PCR-based site-directed 
mutagenesis was used to introduce Cd79b mutations. Se-
quence-confirmed Myd88 and Cd79b genes were then trans-
ferred into pMXs-IRES-GFP vectors (Kitamura et al., 2003) 
either individually or as dual-expression vectors (Fig. 1 A). To 
modulate protein translation, short open reading frames were 
inserted into the 5′ UTRs of Cd79b coding sequence (Fig. 
S1). Retroviral vectors containing Myd88 or Cd79b or dual 
Myd88 and Cd79b were transfected into Phoenix ecotropic 
packaging cells (ATCC) using calcium phosphate precipita-
tion (Swift et al., 2001). Supernatants containing retroviral 
particles were collected 48 and 72  h after transfection and 
frozen at −80°C until use.
retroviral transduction of mature B cells
MD4 transgenic mice were given 5 mg HEL to provide a 
pulse of antigen to activate HEL-specific B cells 6 h before 
removing the spleen and preparing a single-cell suspension 
and washing twice with fresh complete RPMI by centri-
fugation at 300 g for 5 min at 8°C. Splenocytes were cul-
tured at 4 × 106 cells/ml in complete RPMI containing 10 
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µg/ml anti-CD40 antibody (FGK4.5; Bio X Cell) for 24 h. 
For splenocytes from nontransgenic C57BL/6 mice, 7 µg/ml 
anti-IgM (Jackson ImmunoResearch Laboratories, Inc.) was 
also included during the initial 24-h activation culture. After 
24 h, the cells were washed twice in RPMI and spin-infected 
in 6-well plates at 920 g for 90 min at room temperature with 
retrovirus supernatant containing 10 µl/ml DOT AP (Roche). 
The cells were then placed back in fresh RPMI containing 
10 µg/ml anti-CD40 but no BCR ligands for HEL-specific 
B cells, or anti-CD40 plus 10 µg/ml anti-IgM for nontrans-
genic B cells for 36 h. The transduced cells were then washed 
three times with fresh complete RPMI by centrifugation at 
300 g for 5 min at 8°C, and any remaining media contain-
ing trace amount of anti-CD40 and/or anti-IgM antibodies 
was carefully removed. The number of live cells was deter-
mined by hemocytometer counting of Trypan blue–negative 
cells, and the percentage of EGFP+ 7AAD− cells was deter-
mined by flow cytometry. Washed, transduced cells were then 
cultured in 24-well plates at 106 cells/ml in fresh complete 
RPMI without anti-CD40 or BCR ligand, with the start of 
the mitogen-free cultures designated “day 0.”
Adoptive transfer and cell culture
Retrovirally transduced B cells were recovered 36  h after 
transduction and washed, and live cells were enumerated by 
Trypan blue exclusion. Live cells (2–10 × 106), consisting 
of a mixture of transduced and nontransduced B cells, were 
transferred into each recipient mouse through lateral tail vein 
injection. Recipient mice were sacrificed after 5–11 d and 
their spleens analyzed for the amount of EGFP+ HEL-bind-
ing mature B cells. For cell culture experiments, cells were 
washed and cultured at 106 cells/ml fresh RPMI media sup-
plemented with 10% vol/vol FCS and 2% vol/vol penicil-
lin, streptomycin, and glutamine without B cell mitogens in 
24-well plates. The start of the cultures was designated “day 
0.” The number of EGFP+ cells on the subsequent days in 
culture was then determined by hemocytometer counting of 
Trypan blue–negative cells and flow cytometric analysis of 
the percentage of EGFP+ 7AAD− cells and expressed as rela-
tive amount compared with day 0.
Flow cytometric analysis
Single-cell suspensions were prepared and transferred to 96-
well round-bottom plates. Cells were then incubated for 30 
min at 4°C with antibody cocktails containing appropriate 
combination and dilution of antibodies in flow cytometry 
buffer (PBS with 2% vol/vol bovine serum and 0.1% wt/vol 
sodium azide). Cells were then washed twice and resuspended 
in flow cytometric buffer containing 7AAD for analysis on an 
LSR II or LSR Fortessa flow cytometer (BD). The following 
antibodies were used: anti-B220, CD19, IgMa, CD79B, Qdot 
605–streptavidin, and 7AAD. HyHEL9 antibody conjugated 
to Alex Fluor 647 was performed in-house with a monoclo-
nal antibody labeling kit (Molecular Probes). Cells were first 
stained with 1 µg/ml HEL protein before staining with the 
HyHEL9 antibody. FlowJo (Tree Star) software was used to 
analyze the flow cytometry data.
Western blot analysis
Transduced B cells were cultured without anti-CD40 for 
24 h and EGFP+ cells sorted using FAC SAria I and II (BD) 
cell sorter and washed twice with cold PBS. For Western blot 
analysis, cytoplasmic proteins were extracted from 106 cells 
using the NE-PER protein extraction kit (78833; Thermo 
Fisher Scientific) per the manufacturer’s protocol. For Endo 
H treatment, 5 × 105 cell equivalents in 9-µl protein lysates 
were mixed with 1 µl of 10× glycoprotein denaturing buffer, 
heated at 100°C for 10 min, and incubated at 37°C with the 
addition of 2 µl 10× G5 reaction buffer and 1 µl Endo H in 
a total volume of 20 µl for 1 h (P0702; New England Bio-
labs, Inc.). At the end of the reaction, 10 µl 3× SDS sample 
buffer (0.2 M Tris-HCl, pH 6.8, 10% wt/vol SDS, 30% vol/
vol glycerol, 10% vol/vol β-mercaptoethanol, and bromophe-
nol blue) was added to stop the reaction, and samples were 
stored at −20°C until use.
Lysates were heated briefly at 100°C, microcentrifuged 
for 1 min at 13,000 rpm, and resolved on a 15% polyacryl-
amide gel. Resolved proteins were then transferred onto a 
polyvinylidene fluoride membrane (Bio-Rad Laboratories). 
Nonspecific antibody binding to the membrane was blocked 
with 5% wt/vol skim milk in TBST (10 mM Tris-HCl, pH 
7.5, 150 mM NaCl, and 0.1% vol/vol Tween 20) for 30 min 
at room temperature and then probed overnight at 4°C with 
antibodies to IgM and CD79B. After primary antibody incu-
bation, the membrane was washed three times with TBST and 
incubated with HRP-conjugated anti-rabbit IgG secondary 
antibody for 60 min at room temperature. Membranes were 
then washed at least five times with TBST before detec-
tion using enhanced chemiluminescence detection reagent 
(PerkinElmer) and developed in a darkroom onto Kodak 
films. Membranes were reprobed with anti-α/β-tubulin anti-
bodies as loading control.
Microarray and quantitative Pcr analysis
For microarray analysis, sorted cells were resuspended in 
TRIzol. Phase separation was performed by the addition of 
chloroform and centrifugation at 12,000 g for 15 min, followed 
by isopropanol RNA precipitation. The air-dried RNA pellet 
was dissolved in RNase-free water, and mRNA expression 
was analyzed on Affymetrix mouse ST 1.0 arrays as per the 
manufacturer’s instructions. Microarray data were subjected to 
quality control, normalization, and differential expression anal-
ysis in limma (Ritchie et al., 2015). Quality control reviewed 
reconstructed array images, distribution of probe intensities, 
M(log ratio) versus A(mean average) plots, fitting of a probe 
level model in the oligo package (Carvalho and Irizarry, 2010) 
to generate box plots of relative log expression and normalized 
unscaled standard errors. One of three independent samples 
of sorted cells in each experimental group was excluded on 
the basis of insufficient quality. The final set of eight sam-
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ples was normalized using PLM (Carvalho and Irizarry, 2010) 
and resulting probe weights were used to derive weights for 
transcript expression estimates on each array suitable for use 
with limma in a linear model, comparing gene expression in 
MYD88L265P cells with each of the other groups. CAM ERA 
(Wu and Smyth, 2012) was used to query for enrichment of 
differentially expressed genes against predefined sets of hall-
mark, curated, and immunological signature gene sets defined 
in MSigDB (Subramanian et al., 2005). Microarray data that 
support the findings of this study have been deposited in Gene 
Expression Omnibus (accession no. GSE99775).
For quantitative RT-PCR, total RNA was extracted 
from sorted EGFP+ cells with TRIzol (Thermo Fisher Sci-
entific). For each sample, an equal amount of total RNA was 
reverse-transcribed to cDNA with SuperScript II reverse 
transcription (Invitrogen) for 2 h at 42°C. Dilution (1:100) 
of the cDNA stock was used to set up TaqMan quantita-
tive RT-PCR on an ABI7500 instrument (Applied Biosys-
tems) using the following mouse TaqMan probes (Thermo 
Fisher Scientific): Myd88 (Mm00440338_m1), Cd79a 
(Mm00432423_m1), Cd79b, (Mm00434143_m1), and Ighm 
(Mm01718955_g1). Data were normalized to β-actin expres-
sion: ACTB-F, 5′-GCC TTC CTT CTT GGG TAT GGAA-3′, 
ACTB-R, 5′-GGC GGA CTG TTA CTG AGC TG-3′.
statistical analysis
Data were generated and analyzed using Prism version 
5.0 (GraphPad Software). Statistically significant p-values 
of <0.05, <0.01, and <0.001, determined by two-tailed 
unpaired Student’s t test or ANO VA, are indicated where 
applicable.
online supplemental material
Fig. S1 shows open reading frames inserted into Cd79b 5′ 
UTRs. Fig. S2 shows CD138 expression on EGFP+ cells 
transduced with the indicated vector and analyzed 11 d 
after adoptive transfer into Rag1−/− recipient mice. Table S1 
shows gene set enrichment analysis of MYD88L265P- versus 
CARD11L232LI-expressing B cells. Table S2 shows hallmark 
gene sets enriched in MYD88L265P- versus CARD11L232LI-ex-
pressing B cells. Table S3 shows curated gene sets enriched 
in MYD88L265P- versus CARD11L232LI-expressing B cells. 
Table S4 shows a complete microarray dataset comparing 
B cells expressing MYD88L265P with cells expressing empty 
vector, CARD11L232LI, or IKB KBK171E. Tables S1–S4 are 
provided as Excel files.
AcknoWLedgMents
We thank the Australian Phenomics Facility for expert care and genotyping of ani-
mals, the Australian Cancer Research Foundation Biomolecular Resource Facility for 
sequencing and microarray, and the John Curtin School of Medical Research image 
and cytometry facility for cell sorting.
J.Q. Wang was supported by an Australian Postgraduate Award and an Aus-
tralian National University Postgraduate Scholarship. H.M. Yoo was supported by a 
Korean Visiting Scientist Training Award Fellowship from the Korea Health Industry 
Development Institute (HI15C1075). C.C. Goodnow was supported by National Health 
and Medical Research Council (NHM RC) Australia Fellowship 585490 and NHM RC 
Senior Principal Research Fellowship 1081858. The research was supported by NHM 
RC grants to C.C. Goodnow (1016953 and 1113904) and to K. Horikawa (1086770).
The authors declare no competing financial interests.
Author contributions: J.Q. Wang designed and performed experiments, ana-
lyzed data, and drafted the manuscript. Y.S. Jeelall, E.L. Batchelor, and S.M. Kaya as-
sisted with experiments. P. Humburg analyzed the microarray data. H.M. Yoo 
performed and analyzed the quantitative PCR experiments. K. Horikawa conceived 
the study and constructed the vectors. C.C. Goodnow and K. Horikawa initiated, de-
signed, supervised, and interpreted the experiments and revised the manuscript.
Submitted: 1 September 2016
Revised: 30 April 2017
Accepted: 13 June 2017
reFerences
Akira, S., and K. Takeda. 2004. Toll-like receptor signalling. Nat. Rev. Immunol. 
4:499–511. http ://dx .doi .org /10 .1038 /nri1391
Avbelj, M., O.O. Wolz, O. Fekonja, M. Benčina, M. Repič, J. Mavri, J. Krüger, 
C. Schärfe, M. Delmiro Garcia, G. Panter, et al. 2014. Activation of 
lymphoma-associated MyD88 mutations via allostery-induced TIR-
domain oligomerization. Blood. 124:3896–3904. http ://dx .doi .org /10 
.1182 /blood -2014 -05 -573188
Bell, S.E., and C.C. Goodnow. 1994. A selective defect in IgM antigen recep-
tor synthesis and transport causes loss of cell surface IgM expression on 
tolerant B lymphocytes. EMBO J. 13:816–826.
Bonetti, P., M. Testoni, M. Scandurra, M. Ponzoni, R. Piva, A.A. Mensah, 
A. Rinaldi, I. Kwee, M.G. Tibiletti, J. Iqbal, et al. 2013. Deregulation of 
ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell 
lymphoma. Blood. 122:2233–2241. http ://dx .doi .org /10 .1182 /blood 
-2013 -01 -475772
Bories, J.C., D.M. Willerford, D. Grévin, L. Davidson, A. Camus, P. Martin, 
D. Stéhelin, and F.W. Alt. 1995. Increased T-cell apoptosis and terminal 
B-cell differentiation induced by inactivation of the Ets-1 proto-
oncogene. Nature. 377:635–638. http ://dx .doi .org /10 .1038 /377635a0
Calvo, S.E., D.J. Pagliarini, and V.K. Mootha. 2009. Upstream open reading 
frames cause widespread reduction of protein expression and are 
polymorphic among humans. Proc. Natl. Acad. Sci. USA. 106:7507–7512. 
http ://dx .doi .org /10 .1073 /pnas .0810916106
Cambier, J.C., C.M. Pleiman, and M.R. Clark. 1994. Signal transduction 
by the B cell antigen receptor and its coreceptors. Annu. Rev. Immunol. 
12:457–486. http ://dx .doi .org /10 .1146 /annurev .iy .12 .040194 .002325
Carvalho, B.S., and R.A. Irizarry. 2010. A framework for oligonucleotide 
microarray preprocessing. Bioinformatics. 26:2363–2367. http ://dx .doi 
.org /10 .1093 /bioinformatics /btq431
Chan, V.W., F. Meng, P. Soriano, A.L. DeFranco, and C.A. Lowell. 1997. 
Characterization of the B lymphocyte populations in Lyn-deficient mice 
and the role of Lyn in signal initiation and down-regulation. Immunity. 
7:69–81. http ://dx .doi .org /10 .1016 /S1074 -7613(00)80511 -7
Cornall, R.J., J.G. Cyster, M.L. Hibbs, A.R. Dunn, K.L. Otipoby, E.A. Clark, 
and C.C. Goodnow. 1998. Polygenic autoimmune traits: Lyn, CD22, and 
SHP-1 are limiting elements of a biochemical pathway regulating BCR 
signaling and selection. Immunity. 8:497–508. http ://dx .doi .org /10 .1016 
/S1074 -7613(00)80554 -3
Cyster, J.G., S.B. Hartley, and C.C. Goodnow. 1994. Competition for 
follicular niches excludes self-reactive cells from the recirculating B-cell 
repertoire. Nature. 371:389–395. http ://dx .doi .org /10 .1038 /371389a0
Davis, R.E., V.N. Ngo, G. Lenz, P. Tolar, R.M. Young, P.B. Romesser, H. 
Kohlhammer, L. Lamy, H. Zhao, Y. Yang, et al. 2010. Chronic active 
B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 
463:88–92. http ://dx .doi .org /10 .1038 /nature08638
 o
n
 M
arch 4, 2018
jem.rupress.org
D
ow
nloaded from
 
2775JEM Vol. 214, No. 9
Durand, C.A., K. Hartvigsen, L. Fogelstrand, S. Kim, S. Iritani, B. 
Vanhaesebroeck, J.L. Witztum, K.D. Puri, and M.R. Gold. 2009. 
Phosphoinositide 3-kinase p110 delta regulates natural antibody 
production, marginal zone and B-1 B cell function, and autoantibody 
responses. J. Immunol. 183:5673–5684. http ://dx .doi .org /10 .4049 /
jimmunol .0900432
Enders, A., P. Bouillet, H. Puthalakath, Y. Xu, D.M. Tarlinton, and A. Strasser. 
2003. Loss of the pro-apoptotic BH3-only Bcl-2 family member Bim 
inhibits BCR stimulation-induced apoptosis and deletion of autoreactive 
B cells. J. Exp. Med. 198:1119–1126. http ://dx .doi .org /10 .1084 /jem 
.20030411
Gazumyan, A., A. Reichlin, and M.C. Nussenzweig. 2006. Ig beta tyrosine 
residues contribute to the control of B cell receptor signaling by 
regulating receptor internalization. J. Exp. Med. 203:1785–1794. http ://
dx .doi .org /10 .1084 /jem .20060221
Gerondakis, S., and U. Siebenlist. 2010. Roles of the NF-kappaB pathway in 
lymphocyte development and function. Cold Spring Harb. Perspect. Biol. 
2:a000182. http ://dx .doi .org /10 .1101 /cshperspect .a000182
Glynne, R., G. Ghandour, J. Rayner, D.H. Mack, and C.C. Goodnow. 2000. 
B-lymphocyte quiescence, tolerance and activation as viewed by global 
gene expression profiling on microarrays. Immunol. Rev. 176:216–246. 
http ://dx .doi .org /10 .1034 /j .1600 -065X .2000 .00614 .x
Goodnow, C.C. 2007. Multistep pathogenesis of autoimmune disease. Cell. 
130:25–35. http ://dx .doi .org /10 .1016 /j .cell .2007 .06 .033
Goodnow, C.C.J., J. Crosbie, S. Adelstein, T.B. Lavoie, S.J. Smith-Gill, R.A. 
Brink, H. Pritchard-Briscoe, J.S. Wotherspoon, R.H. Loblay, K. Raphael, 
et al. 1988. Altered immunoglobulin expression and functional silencing 
of self-reactive B lymphocytes in transgenic mice. Nature. 334:676–682. 
http ://dx .doi .org /10 .1038 /334676a0
Grillot-Courvalin, C., J.C. Brouet, F. Piller, L.Z. Rassenti, S. Labaume, 
G.J. Silverman, L. Silberstein, and T.J. Kipps. 1992. An anti-B cell 
autoantibody from Wiskott-Aldrich syndrome which recognizes i blood 
group specificity on normal human B cells. Eur. J. Immunol. 22:1781–
1788. http ://dx .doi .org /10 .1002 /eji .1830220717
Gross, A.J., J.R. Lyandres, A.K. Panigrahi, E.T. Prak, and A.L. DeFranco. 
2009. Developmental acquisition of the Lyn-CD22-SHP-1 inhibitory 
pathway promotes B cell tolerance. J. Immunol. 182:5382–5392. http ://
dx .doi .org /10 .4049 /jimmunol .0803941
Hayden, M.S., and S. Ghosh. 2012. NF-κB, the first quarter-century: 
remarkable progress and outstanding questions. Genes Dev. 26:203–234. 
http ://dx .doi .org /10 .1101 /gad .183434 .111
Healy, J.I., R.E. Dolmetsch, L.A. Timmerman, J.G. Cyster, M.L. Thomas, 
G.R. Crabtree, R.S. Lewis, and C.C. Goodnow. 1997. Different nuclear 
signals are activated by the B cell receptor during positive versus negative 
signaling. Immunity. 6:419–428. http ://dx .doi .org /10 .1016 /S1074 
-7613(00)80285 -X
Hollenhorst, P.C., L.P. McIntosh, and B.J. Graves. 2011. Genomic and 
biochemical insights into the specificity of ETS transcription factors. 
Annu. Rev. Biochem. 80:437–471. http ://dx .doi .org /10 .1146 /annurev 
.biochem .79 .081507 .103945
Hsu, F.J., and R. Levy. 1995. Preferential use of the VH4 Ig gene family by 
diffuse large-cell lymphoma. Blood. 86:3072–3082.
Hunter, Z.R., L. Xu, G. Yang, Y. Zhou, X. Liu, Y. Cao, R.J. Manning, C. 
Tripsas, C.J. Patterson, P. Sheehy, and S.P. Treon. 2014. The genomic 
landscape of Waldenstrom macroglobulinemia is characterized by 
highly recurring MYD88 and WHIM-like CXCR4 mutations, and 
small somatic deletions associated with B-cell lymphomagenesis. Blood. 
123:1637–1646. http ://dx .doi .org /10 .1182 /blood -2013 -09 -525808
Jeelall, Y.S., J.Q. Wang, H.D. Law, H. Domaschenz, H.K. Fung, A. Kallies, 
S.L. Nutt, C.C. Goodnow, and K. Horikawa. 2012. Human lymphoma 
mutations reveal CARD11 as the switch between self-antigen-induced 
B cell death or proliferation and autoantibody production. J. Exp. Med. 
209:1907–1917. http ://dx .doi .org /10 .1084 /jem .20112744
Kitamura, T., Y. Koshino, F. Shibata, T. Oki, H. Nakajima, T. Nosaka, and 
H. Kumagai. 2003. Retrovirus-mediated gene transfer and expression 
cloning: powerful tools in functional genomics. Exp. Hematol. 31:1007–
1014. http ://dx .doi .org /10 .1016 /S0301 -472X(03)00260 -1
Knittel, G., P. Liedgens, D. Korovkina, J.M. Seeger, Y. Al-Baldawi, M. Al-
Maarri, C. Fritz, K. Vlantis, S. Bezhanova, A.H. Scheel, et al. German 
International Cancer Genome Consortium Molecular Mechanisms 
in Malignant Lymphoma by Sequencing Project Consortium. 2016. 
B-cell-specific conditional expression of Myd88p.L252P leads to the 
development of diffuse large B-cell lymphoma in mice. Blood. 127:2732–
2741. http ://dx .doi .org /10 .1182 /blood -2015 -11 -684183
Lam, K.P., R. Kühn, and K. Rajewsky. 1997. In vivo ablation of surface 
immunoglobulin on mature B cells by inducible gene targeting results in 
rapid cell death. Cell. 90:1073–1083. http ://dx .doi .org /10 .1016 /S0092 
-8674(00)80373 -6
Lamagna, C., P. Scapini, J.A. van Ziffle, A.L. DeFranco, and C.A. Lowell. 2013. 
Hyperactivated MyD88 signaling in dendritic cells, through specific 
deletion of Lyn kinase, causes severe autoimmunity and inflammation. 
Proc. Natl. Acad. Sci. USA. 110:E3311–E3320. http ://dx .doi .org /10 
.1073 /pnas .1300617110
Lamagna, C., Y. Hu, A.L. DeFranco, and C.A. Lowell. 2014. B cell-specific loss 
of Lyn kinase leads to autoimmunity. J. Immunol. 192:919–928. http ://dx 
.doi .org /10 .4049 /jimmunol .1301979
Lenz, G., and L.M. Staudt. 2010. Aggressive lymphomas. N. Engl. J. Med. 
362:1417–1429. http ://dx .doi .org /10 .1056 /NEJMra0807082
Lenz, G., R.E. Davis, V.N. Ngo, L. Lam, T.C. George, G.W. Wright, S.S. 
Dave, H. Zhao, W. Xu, A. Rosenwald, et al. 2008. Oncogenic CARD11 
mutations in human diffuse large B cell lymphoma. Science. 319:1676–
1679. http ://dx .doi .org /10 .1126 /science .1153629
Lin, S.C., Y.C. Lo, and H. Wu. 2010. Helical assembly in the MyD88-IRAK4-
IRAK2 complex in TLR/IL-1R signalling. Nature. 465:885–890. http 
://dx .doi .org /10 .1038 /nature09121
Lohr, J.G., P. Stojanov, S.L. Carter, P. Cruz-Gordillo, M.S. Lawrence, D. Auclair, 
C. Sougnez, B. Knoechel, J. Gould, G. Saksena, et al. Multiple Myeloma 
Research Consortium. 2014. Widespread genetic heterogeneity in 
multiple myeloma: implications for targeted therapy. Cancer Cell. 25:91–
101. http ://dx .doi .org /10 .1016 /j .ccr .2013 .12 .015
Lossos, I.S., C.Y. Okada, R. Tibshirani, R. Warnke, J.M. Vose, T.C. Greiner, and 
R. Levy. 2000. Molecular analysis of immunoglobulin genes in diffuse 
large B-cell lymphomas. Blood. 95:1797–1803.
Luo, W., J. Mayeux, T. Gutierrez, L. Russell, A. Getahun, J. Müller, T. Tedder, 
J. Parnes, R. Rickert, L. Nitschke, et al. 2014. A balance between B 
cell receptor and inhibitory receptor signaling controls plasma cell 
differentiation by maintaining optimal Ets1 levels. J. Immunol. 193:909–
920. http ://dx .doi .org /10 .4049 /jimmunol .1400666
Mori, S., R.E. Rempel, J.T. Chang, G. Yao, A.S. Lagoo, A. Potti, A. Bild, and 
J.R. Nevins. 2008. Utilization of pathway signatures to reveal distinct 
types of B lymphoma in the Emicro-myc model and human diffuse 
large B-cell lymphoma. Cancer Res. 68:8525–8534. http ://dx .doi .org /10 
.1158 /0008 -5472 .CAN -08 -1329
Ngo, V.N., R.M. Young, R. Schmitz, S. Jhavar, W. Xiao, K.H. Lim, H. 
Kohlhammer, W. Xu, Y. Yang, H. Zhao, et al. 2011. Oncogenically active 
MYD88 mutations in human lymphoma. Nature. 470:115–119. http ://
dx .doi .org /10 .1038 /nature09671
Nutt, S.L., A.M. Morrison, P. Dörfler, A. Rolink, and M. Busslinger. 1998. 
Identification of BSAP (Pax-5) target genes in early B-cell development 
by loss- and gain-of-function experiments. EMBO J. 17:2319–2333. 
http ://dx .doi .org /10 .1093 /emboj /17 .8 .2319
Ottensmeier, C.H., A.R. Thompsett, D. Zhu, B.S. Wilkins, J.W. Sweetenham, 
and F.K. Stevenson. 1998. Analysis of VH genes in follicular and diffuse 
lymphoma shows ongoing somatic mutation and multiple isotype tran-
scripts in early disease with changes during disease progression. Blood. 
91:4292–4299.
 o
n
 M
arch 4, 2018
jem.rupress.org
D
ow
nloaded from
 
Cooperation between MYD88L265P and CD79B | Wang et al.2776
Pascual, V., K. Victor, D. Lelsz, M.B. Spellerberg, T.J. Hamblin, K.M. Thompson, 
I. Randen, J. Natvig, J.D. Capra, and F.K. Stevenson. 1991. Nucleotide se-
quence analysis of the V regions of two IgM cold agglutinins. Evidence 
that the VH4-21 gene segment is responsible for the major cross-reactive 
idiotype. J. Immunol. 146:4385–4391.
Pasqualucci, L., M. Compagno, J. Houldsworth, S. Monti, A. Grunn, S.V. 
Nandula, J.C. Aster, V.V. Murty, M.A. Shipp, and R. Dalla-Favera. 2006. 
Inactivation of the PRDM1/BLI MP1 gene in diffuse large B cell 
lymphoma. J. Exp. Med. 203:311–317. http ://dx .doi .org /10 .1084 /jem 
.20052204
Poulain, S., C. Roumier, S. Galiègue-Zouitina, A. Daudignon, C. Herbaux, 
R. Aiijou, A. Lainelle, N. Broucqsault, E. Bertrand, S. Manier, et al. 2013. 
Genome wide SNP array identified multiple mechanisms of genetic 
changes in Waldenstrom macroglobulinemia. Am. J. Hematol. 88:948–
954. http ://dx .doi .org /10 .1002 /ajh .23545
Puente, X.S., M. Pinyol, V. Quesada, L. Conde, G.R. Ordóñez, N. Villamor, G. 
Escaramis, P. Jares, S. Beà, M. González-Díaz, et al. 2011. Whole-genome 
sequencing identifies recurrent mutations in chronic lymphocytic 
leukaemia. Nature. 475:101–105. http ://dx .doi .org /10 .1038 /
nature10113
Pugh-Bernard, A.E., G.J. Silverman, A.J. Cappione, M.E. Villano, D.H. Ryan, 
R.A. Insel, and I. Sanz. 2001. Regulation of inherently autoreactive 
VH4-34 B cells in the maintenance of human B cell tolerance. J. Clin. 
Invest. 108:1061–1070. http ://dx .doi .org /10 .1172 /JCI200112462
Reed, J.H., J. Jackson, D. Christ, and C.C. Goodnow. 2016. Clonal redemption 
of autoantibodies by somatic hypermutation away from self-reactivity 
during human immunization. J. Exp. Med. 213:1255–1265. http ://dx .doi 
.org /10 .1084 /jem .20151978
Reth, M., and J. Wienands. 1997. Initiation and processing of signals from the 
B cell antigen receptor. Annu. Rev. Immunol. 15:453–479. http ://dx .doi 
.org /10 .1146 /annurev .immunol .15 .1 .453
Ritchie, M.E., B. Phipson, D. Wu, Y. Hu, C.W. Law, W. Shi, and G.K. 
Smyth. 2015. limma powers differential expression analyses for RNA-
sequencing and microarray studies. Nucleic Acids Res. 43:e47. http ://dx 
.doi .org /10 .1093 /nar /gkv007
Rui, L., C.G. Vinuesa, J. Blasioli, and C.C. Goodnow. 2003. Resistance to 
CpG DNA-induced autoimmunity through tolerogenic B cell antigen 
receptor ERK signaling. Nat. Immunol. 4:594–600. http ://dx .doi .org /10 
.1038 /ni924
Rui, L., J.I. Healy, J. Blasioli, and C.C. Goodnow. 2006. ERK signaling is a 
molecular switch integrating opposing inputs from B cell receptor and 
T cell cytokines to control TLR4-driven plasma cell differentiation. J. 
Immunol. 177:5337–5346. http ://dx .doi .org /10 .4049 /jimmunol .177 .8 
.5337
Rui, L., R. Schmitz, M. Ceribelli, and L.M. Staudt. 2011. Malignant pirates 
of the immune system. Nat. Immunol. 12:933–940. http ://dx .doi .org /10 
.1038 /ni .2094
Silberstein, L.E., L.C. Jefferies, J. Goldman, D. Friedman, J.S. Moore, P.C. 
Nowell, D. Roelcke, W. Pruzanski, J. Roudier, and G.J. Silverman. 1991. 
Variable region gene analysis of pathologic human autoantibodies to the 
related i and I red blood cell antigens. Blood. 78:2372–2386.
Srinivasan, L., Y. Sasaki, D.P. Calado, B. Zhang, J.H. Paik, R.A. DePinho, J.L. 
Kutok, J.F. Kearney, K.L. Otipoby, and K. Rajewsky. 2009. PI3 kinase 
signals BCR-dependent mature B cell survival. Cell. 139:573–586. http 
://dx .doi .org /10 .1016 /j .cell .2009 .08 .041
Subramanian, A., P. Tamayo, V.K. Mootha, S. Mukherjee, B.L. Ebert, M.A. 
Gillette, A. Paulovich, S.L. Pomeroy, T.R. Golub, E.S. Lander, and J.P. 
Mesirov. 2005. Gene set enrichment analysis: a knowledge-based 
approach for interpreting genome-wide expression profiles. Proc. Natl. 
Acad. Sci. USA. 102:15545–15550. http ://dx .doi .org /10 .1073 /pnas 
.0506580102
Swift, S., J. Lorens, P. Achacoso, and G.P. Nolan. 2001. Rapid production of 
retroviruses for efficient gene delivery to mammalian cells using 293T 
cell-based systems. Curr. Protoc. Immunol. Chapter 10:Unit 10.17C.
Thome, M. 2004. CAR MA1, BCL-10 and MALT1 in lymphocyte 
development and activation. Nat. Rev. Immunol. 4:348–359. http ://dx 
.doi .org /10 .1038 /nri1352
Treon, S.P., L. Xu, G. Yang, Y. Zhou, X. Liu, Y. Cao, P. Sheehy, R.J. Manning, 
C.J. Patterson, C. Tripsas, et al. 2012. MYD88 L265P somatic mutation 
in Waldenström’s macroglobulinemia. N. Engl. J. Med. 367:826–833. http 
://dx .doi .org /10 .1056 /NEJMoa1200710
Verstrepen, L., I. Carpentier, and R. Beyaert. 2014. The biology of A20-
binding inhibitors of NF-kappaB activation (ABINs). Adv. Exp. Med. 
Biol. 809:13–31. http ://dx .doi .org /10 .1007 /978 -1 -4939 -0398 -6 _2
Vyncke, L., C. Bovijn, E. Pauwels, T. Van Acker, E. Ruyssinck, E. Burg, J. 
Tavernier, and F. Peelman. 2016. Reconstructing the TIR side of the 
Myddosome: a paradigm for TIR-TIR interactions. Structure. 24:437–
447. http ://dx .doi .org /10 .1016 /j .str .2015 .12 .018
Wang, D., S.A. John, J.L. Clements, D.H. Percy, K.P. Barton, and L.A. Garrett-
Sinha. 2005. Ets-1 deficiency leads to altered B cell differentiation, 
hyperresponsiveness to TLR9 and autoimmune disease. Int. Immunol. 
17:1179–1191. http ://dx .doi .org /10 .1093 /intimm /dxh295
Wang, J.Q., Y.S. Jeelall, B. Beutler, K. Horikawa, and C.C. Goodnow. 2014. 
Consequences of the recurrent MYD88L265P somatic mutation for B cell 
tolerance. J. Exp. Med. 211:413–426. http ://dx .doi .org /10 .1084 /jem 
.20131424
Wang, J.Q., B. Beutler, C.C. Goodnow, and K. Horikawa. 2016. Inhibiting 
TLR9 and other UNC93B1-dependent TLRs paradoxically increases 
accumulation of MYD88L265P plasmablasts in vivo. Blood. 128:1604–
1608. http ://dx .doi .org /10 .1182 /blood -2016 -03 -708065
Wang, L., M.S. Lawrence, Y. Wan, P. Stojanov, C. Sougnez, K. Stevenson, L. 
Werner, A. Sivachenko, D.S. DeLuca, L. Zhang, et al. 2011. SF3B1 and 
other novel cancer genes in chronic lymphocytic leukemia. N. Engl. J. 
Med. 365:2497–2506. http ://dx .doi .org /10 .1056 /NEJMoa1109016
Wilson, W.H., R.M. Young, R. Schmitz, Y. Yang, S. Pittaluga, G. Wright, C.J. 
Lih, P.M. Williams, A.L. Shaffer, J. Gerecitano, et al. 2015. Targeting B cell 
receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat. 
Med. 21:922–926. http ://dx .doi .org /10 .1038 /nm .3884
Wu, D., and G.K. Smyth. 2012. Camera: a competitive gene set test accounting 
for inter-gene correlation. Nucleic Acids Res. 40:e133. http ://dx .doi .org 
/10 .1093 /nar /gks461
Xu, L., Z.R. Hunter, G. Yang, Y. Zhou, Y. Cao, X. Liu, E. Morra, A. Trojani, 
A. Greco, L. Arcaini, et al. 2013. MYD88 L265P in Waldenström 
macroglobulinemia, immunoglobulin M monoclonal gammopathy, 
and other B-cell lymphoproliferative disorders using conventional and 
quantitative allele-specific polymerase chain reaction. Blood. 121:2051–
2058. http ://dx .doi .org /10 .1182 /blood -2012 -09 -454355
Young, R.M., A.L. Shaffer III, J.D. Phelan, and L.M. Staudt. 2015. B-cell 
receptor signaling in diffuse large B-cell lymphoma. Semin. Hematol. 
52:77–85. http ://dx .doi .org /10 .1053 /j .seminhematol .2015 .01 .008
Zhu, D., R.E. Hawkins, T.J. Hamblin, and F.K. Stevenson. 1994. Clonal history 
of a human follicular lymphoma as revealed in the immunoglobulin 
variable region genes. Br. J. Haematol. 86:505–512. http ://dx .doi .org /10 
.1111 /j .1365 -2141 .1994 .tb04780 .x
Zikherman, J., R. Parameswaran, and A. Weiss. 2012. Endogenous antigen 
tunes the responsiveness of naive B cells but not T cells. Nature. 489:160–
164. http ://dx .doi .org /10 .1038 /nature11311
 o
n
 M
arch 4, 2018
jem.rupress.org
D
ow
nloaded from
 
